SCHEMBL169671

SCHEMBL169671

Oc1ccnc2c1ccc1cccnc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 5/20 0.62
CCR8 P51685 5/20 0.62
CCR5 P51681 3/20 0.62
L3MBTL1 Q9Y468 3/20 0.62
LMNA P02545 6/20 0.61
KDM4E B2RXH2 5/20 0.61
MAPT P10636 4/20 0.61
HTT P42858 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
TDP1 Q9NUW8 3/20 0.61
MMP2 P08253 2/20 0.61
TSHR P16473 2/20 0.61
TP53 P04637 2/20 0.61
HSP90AA1 P07900 2/20 0.61
GMNN O75496 1/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2D6 P10635 1/20 0.61
MMP9 P14780 1/20 0.61
ALOX15 P16050 1/20 0.61
NFKB1 P19838 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27825233 0.98 CCR1 (0.61) CCR1CCR8CCR5L3MBTL1LMNA
SCHEMBL1073354 0.83 CCR1 (0.50) CCR1CCR8CCR5L3MBTL1LMNA
Hydrochloric Acid SCHEMBL11825124 0.81 CCR1 (0.48) CCR1CCR8CCR5L3MBTL1LMNA
SCHEMBL28267135 0.81 CCR1 (0.41) CCR1CCR8CCR5L3MBTL1LMNA
SCHEMBL8602672 0.81 CYP1A2 (0.48) CCR1CCR8CCR5L3MBTL1LMNA
Phenanthroline SCHEMBL31549890 0.79 CCR1 (0.89) CCR1CCR8CCR5L3MBTL1LMNA
Phenanthroline SCHEMBL1232224 0.79 CCR1 (0.89) CCR1CCR8CCR5L3MBTL1LMNA
Phenanthroline SCHEMBL11542337 0.79 CCR1 (0.89) CCR1CCR8CCR5L3MBTL1LMNA
Phenanthroline SCHEMBL8690798 0.79 CCR1 (0.89) CCR1CCR8CCR5L3MBTL1LMNA
SCHEMBL169518 0.78 L3MBTL1 (0.61) CCR1CCR8CCR5L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118307514-A Organic electroluminescent compound and organic electroluminescent device comprising the same 罗门哈斯电子材料韩国有限公司 2024-07-09 CN disclosed
WO-2024120467-A1 PHOSPHORAMIDATE MONOSACCHARIDES, PHARMACEUTICAL COMPOSITIONS, AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS SURIO THERAPEUTICS CO. LTD (CN) 2024-06-13 WO disclosed
WO-2024120466-A1 MONOSACCARIDES, PHARMACEUTICAL COMPOSITIONS, AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS SURIO THERAPEUTICS CO., LTD (CN) 2024-06-13 WO disclosed
WO-2024104422-A1 PHOSPHORUS-CONTAINING COMPOUNDS FOR TREATING INFLAMMATORY BOWEL DIESEASE VIVAVISION BIOTECH, INC. (CN) 2024-05-23 WO disclosed
WO-2024104384-A1 INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS NUCMITO PHARMACEUTICALS CO. LTD. (CN) 2024-05-23 WO disclosed
WO-2024094125-A1 LIPID COMPOUNDS, LIPID NANOPARTICLES, AND PHARMACEUTICAL COMPOSITIONS Shanghai Circode Biomed Co., Ltd. (CN) 2024-05-10 WO disclosed
WO-2024094064-A1 PYRIMIDINYLAMINOBENZENES FOR TREATING LUNG CANCER WITH DISTANT METASTASIS SUZHOU PUHE BIOPHARMA CO., LTD (CN) 2024-05-10 WO disclosed
WO-2024061157-A1 CARBOHYDRATE-OLIGONUCLEOTIDE CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) 2024-03-28 WO disclosed
EP-4337628-A1 INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS Nucmito Pharmaceuticals Company Limited (CN) 2024-03-20 EP disclosed
EP-4330256-A1 PYRIMIDINYLAMINOBENZENES FOR LUNG CANCER TREATMENT Suzhou Puhe Biopharma Co., Ltd. (CN) 2024-03-06 EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 US disclosed
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed
US-5773449-A BACTERICIDES FOR HELICOBACTER ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 1998-06-30 US disclosed
EP-0786454-A1 THIOQUINOLONE DERIVATIVE ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 1997-07-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB CCR1 709/4885CCR8 1069/4885CCR5 591/4885
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 CCR1 245/4885CCR8 1610/4885CCR5 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.